Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme

NCT00837824 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped The trial was terminated early due to inadequate study design.

Conditions

Fabry Disease
Chronic Kidney Disease, Stage IV (Severe)

Interventions

BIOLOGICAL: Fabrazyme (agalsidase beta)
BIOLOGICAL: Fabrazyme (agalsidase beta)

Sponsor

Genzyme, a Sanofi Company

Collaborators

[object Object]